Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.52 |
| ▸ | PRSS1 | P07477 | 16/20 | 0.52 |
| ▸ | PRSS2 | P07478 | 12/20 | 0.52 |
| ▸ | PRSS3 | P35030 | 12/20 | 0.52 |
| ▸ | F2 | P00734 | 12/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4686605 | 0.94 | F10 (0.50) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL4683512 | 0.86 | FPR2 (0.56) | F10 | |
| SCHEMBL4679795 | 0.76 | F10 (0.47) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL6986718 | 0.73 | F10 (0.60) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL6996107 | 0.73 | F10 (0.62) | F10PRSS1PRSS2PRSS3F2 | |
| Trifluoroacetic Acid SCHEMBL2325887 | 0.71 | F10 (0.88) | F10PRSS1F2 | |
| Trifluoroacetic Acid SCHEMBL2331599 | 0.70 | F10 (0.89) | F10F2 | |
| Trifluoroacetic Acid SCHEMBL2328739 | 0.70 | F10 (0.89) | F10PRSS1F2 | |
| SCHEMBL2699984 | 0.69 | F10 (0.54) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL6988224 | 0.68 | F10 (0.47) | F10PRSS1F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | F10 9/4885PRSS1 134/4885PRSS2 315/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | F10 9/4885PRSS1 134/4885PRSS2 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.